anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to medicine for treating vertigo, which is colorless and transparent thick liquid. The medicine is composed of components of the following proportion by weight: 0.81 to 0.99% of trisodium citrate dihydrate, 42.32 to 47.27% of glycerol, 0.20 to 0.25% of sodium chloride and 51.60 to 56.57% of distilled water. The trisodium citrate dihydrate and sodium chloride are dissolved in most of distilled water, and an obtained mixture is added to glycerol and is uniformly mixed by a machine. Then, little residual distilled water is injected in the mixture, and finally, the mixture is uniformly mixed by the machine, which obtains a finished product whose pH value is from 6.5 to 8.5. The present invention has the advantages of scientific and novel component, sufficient raw material, low raw material price, convenient taking, safety, short treatment course, good therapeutic effect and low relapse rate. The medical composition product which is prepared by the method that the trisodium citrate dihydrate and the glycerol are used as active components, and carriers acceptable for pharmacy, diluting agents, auxiliary agents, etc. are matched can carry out the complex of blood calcium ions, reduce cell calcium overloads and dewater so as to avoid discomfortable symptoms of patients because of taking large doses of glycerol. The present invention can effectively treat the pathologic change of the vestibular nervous system taking the vertigo as a main symptom.
Aims: Low intensity laser therapy (LILT) has been widely applied in pain relief in several clinical situations. With the advent of new LED-based (light emitting diode)light sources, the need of further clinical experiments aiming to compare the effectiveness between them is paramount. Method: This study proposes an evaluation of analgesic effect in TMD (temporomandibular disorders) using two different LEDs systems, one emitting at the spectral band of red (630 +/-5 nm) and the other at infrared band (850 +/-5 nm), and compare the results with a laser treated control group (780nm diode laser using 105.7 J/cm2). Mandibular range of motion and report of pain were evaluated via appropriate equipment developed to do this end. Power output was 150mW, tip area was 0.5 cm² for both sources. Fluency or dose chosen was 18 J/cm² for each point of application, around the TMJ, on both sides. Five points were irradiated on TMJ, temporal and masseter muscles. Eight irradiation sessions were done and follow up was performed 7 and 30 days, after last session. Thirty patients were enrolled and they were selected randomly for each treatment, resulting in 10 patients per group (infrared LED, red LED and Control Group using infrared Laser).
PURPOSE: To simplify a bonding process by forming a soln. composed of a single phase aq. soln. containing water, a water soluble film forming agent and an acid salt into a film on hard tissue to bond or apply the film to the hard tissue. CONSTITUTION: A primer is a single phase soln. and contains water, a water soluble film forming agent and an acid salt. The film forming agent is an org. monomer, oligomer or polymer being a water soluble liquid substance or a mixture of a water soluble liquid substance and capable of forming a curable continuous or semi-continuous film on the surface of the hard tissue and, for example, there are 2-hydroxyethyl acrylate, polyethylene glycol (400) diacrylate and dimethacrylate. The salt may be a salt of mineral acid or org. acid. The primer is placed on the hard tissue for a required time as it is and an easily volatile auxiliary solvent is removed, for example, by air drying to leave a residual film on the hard tissue and this residual film is covered with an additional forming agent to be cured. By this method, a bonding process is simplified and a bonding time can be shortened.
Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
Compositions, nucleic acid molecules and methods for inducing retinal regeneration and reprogramming of Müller glia (MG) into retinal ganglion cells in a subject are described. Developmental retinal ganglion cell (RGC) transcription factors Pou4f2 and Islet1 increase the Ascl1-induced neurogenic capacity of MG. The combination of Ascl1, Pou4f2 and Islet1 stimulates MG to generate bipolar cells and RGC-like neurons. Likewise, the transcription factor Onecut1, which is expressed in developing retinal cells, but not in MG, induces MG to generate RCG-like cells. Additional transcription factors that can be used include Irx2, Irx5, Neurod2, Ebf1, and Tcf3. MG-derived RGCs can exhibit action potentials in vivo, and display chromatin profiles similar to developing RGCs.
A plaster for treating cervical spondylosis and lumbar disc herniation, and relates to a plaster for treating cervical spondylosis and lumbar disc herniation. Aims to solve the problems that the existing western medicines for treating cervical spondylosis and lumbar disc herniation have long treatment time and are easy to generate medicine side effects and drug resistance. The plaster is prepared from tortoise plastron, turtle shell, astragalus root, fleece-flower root, spatholobus stem, hiraute shiny bugleweed herb, oyster shell, uncaria, gastrodia tuber, common fennel fruit, nutgrass galingale rhizome, cattail pollen, common burreed rhizome, bunge corydalis herb, dandelion, liquorice, Chinese magnoliavine fruit, flax, dog foreleg bone, dog hind leg bone, sesame oil, borax and yellow lead. The invention is a pure Chinese medicinal preparation, has short treatment time and does not generate medicament side effect and medicament resistance. Can be used for treating cervical spondylosis, lumbar intervertebral disc prolapse, joint pain, arthralgia due to wind-cold-dampness, etc., and can reduce morbidity without recurrence. The invention is suitable for preparing the plaster for treating cervical spondylosis and lumbar disc herniation.
Fatalities due to severe hypotension, hypoglycemia, acute pancreatitis and cardiac arrhythmias have been reported in patients treated with pentamidine isethionate, both by the IM and IV routes. Severe hypotension may result after a single IM or IV dose and is more likely with rapid IV administration (see PRECAUTIONS). The administration of the drug should, therefore, be limited to the patients in whom Pneumocystis carinii has been demonstrated. Patients should be closely monitored for the development of serious adverse reactions (see PRECAUTIONS and ADVERSE REACTIONS). 

Extravasations have been reported which, in some instances, proceeded to ulceration, tissue necrosis and/or sloughing at the injection site. While not common, surgical debridement and skin grafting has been necessary in some of these cases; long-term sequelae have been reported. Prevention is the most effective means of limiting the severity of extravasation. The intravenous needle or catheter must be properly positioned and closely observed throughout the period of pentamidine isethionate administration. If extravasation occurs, the injection should be discontinued immediately and restarted in another vein. Because there are no known local treatment measures which have proven to be useful, management of the extravasation should be symptomatic.
Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
High-altitude hypoxia exposure can lead to phospholipase D-mediated lipid metabolism disorder in spleen tissues and induce ferroptosis. Nonetheless, the key genes underlying hypoxia-induced splenic phospholipase D and the ferroptosis pathway remain unclear. This study aimed to establish a hypoxia animal model. Combined transcriptomic and proteomic analyses showed that 95 predicted target genes (proteins) were significantly differentially expressed under hypoxic conditions. Key genes in phospholipase D and ferroptosis pathways under hypoxic exposure were identified by combining Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis techniques. Gene set enrichment analysis (GSEA) showed that the differential gene sets of the phospholipase D and ferroptosis signaling pathways were upregulated in the high-altitude hypoxia group. The genes in the phospholipase D signalling pathway were verified, and the expression levels of KIT and DGKG were upregulated in spleen tissues under hypoxic exposure. Subsequently, the mRNA and protein expression levels of genes from the exogenous pathway such as TFRC, SLC40A1, SLC7A11, TRP53, and FTH1 and those from the endogenous pathway such as GPX4, HMOX1, and ALOX15 differentials in the ferroptosis signalling pathway were verified, and the results indicated significant differential expression. In summary, exposure to high-altitude hypoxia mediated phospholipid metabolism disturbance through the phospholipase D signalling pathway and further induced ferroptosis, leading to splenic injury.
Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
TMAO, a gut microbiota derived byproduct, has been associated with various cardiometabolic diseases by promoting oxidative stress and inflammation. The liver is the main organ for TMAO production and chronic exposure to high doses of TMAO could alter its function. In this study, we evaluated the effect of chronic exposure of high TMAO doses on liver oxidative stress, inflammation, and fibrosis. TMAO was administered daily via gastric gavage to laboratory rats for 3 months. Blood was drawn for the quantification of TMAO, and liver tissues were harvested for the assessment of oxidative stress (MDA, GSH, GSSG, GPx, CAT, and 8-oxo-dG) and inflammation by quantification of IL-1α, TNF-α, IL-10, TGF-β, NOS and COX-2 expression. The evaluation of fibrosis was made by Western blot analysis of α-SMA and Collagen-3 protein expression. Histological investigation and immunohistochemical staining of iNOS were performed in order to assess the liver damage. After 3 months of TMAO exposure, TMAO serum levels enhanced in parallel with increases in MDA and GSSG levels in liver tissue and lower values of GSH and GSH/GSSG ratio as well as a decrease in GPx and CAT activities. Inflammation was also highlighted, with enhanced iNOS, COX-2, and IL-10 expression, without structural changes and without induction of liver fibrosis.
Depression is a major public health problem due to its prevalence and accompanying dysfunction and costs. Depression is undertreated, but even when treatment is adequate and effective, sources of delay in current pharmacologic strategies include: mechanistic delays, those related to the physiologic and behavioral effects of antidepressants; dosing delays in identifying the effective dose; and programmatic delays in identifying an effective agent using sequential monotherapy. This study will randomize 240 patients with Diagnostic and Statistical Manual, 4th Edition (DSM-IV) Major Depressive Disorder (MDD) to 12 week double blind treatment with combined escitalopram and bupropion or each antidepressant administered alone to evaluate whether combined escitalopram and bupropion result in more rapid remission and greater over-all remission than monotherapy. Preclinical and clinical studies suggest that bupropion might prevent one mechanistic delay inherent in escitalopram monotherapy. Rapid dose escalation may counter dosing delays. The simultaneous use of two known antidepressant medications may alleviate programmatic delays inherent in usual sequential monotherapy. Six months follow up and careful assessment of adverse events will address tolerability, acceptability, sustainability, and pharmacoeconomic concerns. If successful, this study might have a significant impact on clinical practice, public health, and depression's cost consequences.
INTRODUCTION: Patients with above-knee amputations (AKA) are normally treated with the traditional socket-mounted prosthesis (SMP), which is associated with a high incidence of problems. Osseointegration has been proposed as a promising option for avoiding many common SMP drawbacks. Several concerns have arisen regarding amputee osseointegration, however, mainly with respect to infection. We report on the safety of a single-stage osseointegration protocol using an antibiotic-loaded hydrogel to coat the intramedullary implant.
MATERIALS AND METHODS: We retrospectively reviewed all AKA cases treated at our center between January 2019 and April 2022, in which a transcutaneous osseointegrated implant was used in a single-stage strategy, together with a rapid-resorbable hydrogel loaded with vancomycin and gentamicin. The specific protocol used, infection rate, implant osseointegration rate and implant survivorship were determined after a minimum follow-up of 12 months.
RESULTS: Eleven osseointegration cases were included in the study, with an average of 16 years post-amputation (range: 3-35 years). After a median follow-up of 24 months (range 12-49 months) no patient had suffered any implant-related infection. Osseointegration of the implant had been achieved in all cases. The mid-term survivorship of the implant in our series was 100 % at the end of follow-up. Radiographs of all cases showed no loosening of the implant. Further, 91 % of the series patients were able to walk without restrictions after the rehabilitation process.
CONCLUSIONS: The single-stage osseointegration protocol for AKA, using a rapid-resorbable hydrogel loaded with vancomycin and gentamicin, yields low rates of implant-related deep infection. This protocol consistently delivers high rates of radiological osseointegration, with no hydrogel-associated complications.
AIMS: Patients with heart failure (HF) and history of myocardial infarction (MI) face a higher risk of disease progression and clinical events. Whether sodium-glucose cotransporter 2 inhibitors may modify clinical trajectory in such individuals remains incompletely understood.
METHODS AND RESULTS: The DAPA-HF and DELIVER trials compared dapagliflozin with placebo in patients with symptomatic HF with left ventricular ejection fraction (LVEF) ≤40% and > 40%, respectively. In this pooled participant-level analysis, we assessed efficacy and safety outcomes by history of MI. The primary outcome in both trials was the composite of cardiovascular death or worsening HF. Of the total of 11 007 patients, 3731 (34%) had a previous MI and were at higher risk of the primary outcome across the spectrum of LVEF in covariate-adjusted models (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.02-1.24). Dapagliflozin reduced the risk of the primary outcome to a similar extent in patients with (HR 0.83, 95% CI 0.72-0.96) and without previous MI (HR 0.76, 95% CI 0.68-0.85; pinteraction = 0.36), with consistent benefits on key secondary outcomes as well. Serious adverse events did not occur more frequently with dapagliflozin, irrespective of previous MI.
CONCLUSION: History of MI confers increased risks of adverse cardiovascular outcomes in patients with HF across the LVEF spectrum, even among those with preserved ejection fraction. Dapagliflozin consistently and safely reduces the risk of cardiovascular death or worsening HF, regardless of previous MI.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents have demonstrated clinical activity with durable responses in relapsed/refractory (r/r) HL. However, patients with a history of allo-HSCT were frequently excluded from clinical trials due to concerns about the risk of graft-versus-host disease (GVHD). We report the clinical history of a patient with refractory classical HL who underwent two allo-HSCTs (first from matched unrelated and second from haploidentical donor) after relapsing on BV and nivolumab and for whom durable remission was finally obtained using BV-pembrolizumab combination for relapse after haploidentical HSCT. Such treatment was associated with the onset of GVHD after only two cycles which led to treatment discontinuation. However, the side effects were rapidly controlled, and after 2 years of follow-up, the patient is still in remission. Our data support the feasibility and efficacy of combining PD-1 blockade with BV to enhance the graft-versus-lymphoma effect after allo-HSCT.
ZIEXTENZO is administered subcutaneously via a single-dose prefilled syringe for manual use.

Prior to use‚ remove the carton from the refrigerator and allow the ZIEXTENZO prefilled syringe to reach room temperature for a minimum of 15-30 minutes. Discard any prefilled syringe left at room temperature for greater than 120 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. ZIEXTENZO is supplied as a clear and colorless to slightly yellowish solution. Do not administer ZIEXTENZO if discoloration or particulates are observed.

The needle cap on the prefilled syringes contains dry natural rubber (derived from latex) which may cause allergic reactions; persons with latex allergies should not administer these products.

Pediatric Patients weighing less than 45 kg

The ZIEXTENZO prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg). The syringe does not bear graduation marks, which are necessary to accurately measure doses of ZIEXTENZO less than 0.6 mL (6 mg) for direct administration to patients. Thus, the direct administration to patients requiring dosing of less than 0.6 mL (6 mg) is not recommended due to the potential for dosing errors. Refer to Table 1.
The guanine deriv. Acyclovir of formula (I) and its hydrates are obtd. by reacting tris-(N2.O.9-trimethylsilyl) guanine with 2-oxa 1,4-butane diol diacetate and hydrolysis of the crude prod. to give cpd. of formula (IV). This is reacted with a base in presence of solvent to obtain (I).
The present invention relates to new solid forms (NSF) of a flavonoid and a coformer. The NSF are co-amorphous solids of flavonoids and amino acids, as well as the solvates of said co-amorphous solids. The flavonoid is selected from quercetin, genistein, fisetin, apigenin, naringenin, rutin, diosmin, among others. The coformer is selected from lysine and arginine. The NSF have enhanced stability, solubility and pharmacological properties over parent polyphenols. The new solid forms are suitable to be used in pharmaceutical compositions, food products, nutritional supplements and the like.
PURPOSE: To obtain a carboplatin composition comprising an aqueous carboplatin solution form buffered at a specific pH, good in stability and useful as a cytostatic agent. CONSTITUTION: This carboplatin composition comprises an aqueous carboplatin solution form buffered at a pH of 2-6.5, preferably 2.5-4.5, more preferably 3.1-3.5. The carboplatin has the maximum solubility of about 22mg/ml, and is usually used in a therapeutic concentration of 8-12mg/ml, especially about 10mg/ml. A phosphate buffer solution is especially used for adjusting the pH in a wide range. The buffer solution is preferably used in the lowest concentration, but must have a sufficient buffering ability. The buffer solution concentration strength of about 0.01-0.03M is generally enough.
FIELD: microbiology, molecular genetics. SUBSTANCE: method involves isolation of vaccine strain of Vibrio cholerae which is alternated specifically by technique of recombinant DNA in order to eliminate its virulence without damage of other components that are necessary for immunity. This attenuation is carried out using digestion of plasmids with restriction endonucleases. These plasmids carry the corresponding DNA nucleotide sequences of V. cholerae. Strains without genes encoding toxin or its fragments are obtained by transfer of ligated gene of digested plasmids and the following selection procedures of recombinants with virulent hosts of V. cholerae in vivo. Vaccine prepared from this strain causes the stable immunity for cholera control. EFFECT: improved method of mutants producing. 7 cl, 1 tbl, 40 dwg, 11 ex
<P>PROBLEM TO BE SOLVED: To provide a composition which prevents or improves wrinkles.  <P>SOLUTION: The wrinkle-improving composition includes (A) astaxanthin and (B) a compound or an extract having a stabilizing effect on dermal matrix component. Drugs, agents for external application, or foods and drinks containing the wrinkle-improving composition are presented. Cosmetics including the wrinkle-improving composition containing (A) astaxanthin and (B) a compound or its extract having a stabilizing effect on dermal matrix component are provided. A method for improving wrinkles in which foods comprising the effective components are taken is provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The invention belongs to the field of medical preparations and relates to a composite paracetamol instant particle and a preparation method thereof. The composite paracetamol instant particle is a white free-flowing particle and has weight loss on drying of 1.89%, bulk specific weight of 0.58g/cm<3> and a dissolution rate of 87.0% when the particle is dissolved for 10min. The preparation method comprises material blending, material feeding, fluidization mixing, slurry preparation, slurry spray granulation, drying and cooling drying. The composite paracetamol instant particles have uniform particle sizes. A remaining ratio of the composite paracetamol instant particles of 20 meshes is 3.14%. An accumulation ratio of the composite paracetamol instant particles of 80 meshes is 83.33%. A dissolution rate is high after tabletting.
OBJECTIVE: This article examined the cost-effectiveness of zanubrutinib and ibrutinib for managing relapsed and refractory chronic lymphocytic leukemia from the viewpoint of payers in China and the US.
METHODS: Markov models were employed to conduct comparisons. Baseline characteristics and clinical data were extracted from the ALPINE study. The cost-effectiveness outcome indicators encompassed cost, quality-adjusted life years, and the incremental cost-effectiveness ratio.
RESULTS: The Markov model analysis revealed that the zanubrutinib group incurred an incremental cost per patient of $-24,586.53 compared to the ibrutinib group. The zanubrutinib group exhibited an incremental utility per capita of 0.28 quality-adjusted life years, resulting in an incremental cost-effectiveness ratio of $-88,068.16 per quality-adjusted life year, which is lower than the payment threshold in China. The willingness-to-pay value in China for 2022 was three times the country's gross domestic product per capita. In the US, patients in the zanubrutinib group experienced per capita incremental costs of $-79,421.56, per capita incremental utility of 0.28 quality-adjusted life years, and an incremental cost-effectiveness ratio of $-284,485.45 per quality-adjusted life year.
CONCLUSION: For Chinese payers, zanubrutinib exhibited superior cost-effectiveness compared to ibrutinib. Zanubrutinib proved to be a more affordable option for US payers when considering the payment threshold.